FONAR to meet with Nasdaq under threat of stock exchange expulsion

TriMed Staff | | Health Imaging | Diagnostic Imaging

Nasdaq’s listing qualifications panel has granted FONAR its filed request for a hearing, at which time the company intends to request the continued listing of its securities based on FONAR’s plan to solicit proxies and hold its annual meeting.

In late June, the Nasdaq Stock Market sent a letter to FONAR, indicating that the company is not in compliance with Marketplace Rules 4350(e) and 4350(g), due to the fact that it had not yet solicited proxies or held its annual meeting for the fiscal year, which ended June 30, 2007.

Nasdaq has scheduled the hearing for late August. The Melville, N.Y.-based FONAR originally planned to hold its annual meeting in June, and said it is anticipating that the panel will render a decision within approximately 30 days after the hearing.

 

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.